Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Cisplatin + Capecitabine in Nasopharyngeal Carcinoma
NCT04850235Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoints: Maximum tolerated dose at 21 days and Incidence of Treatment-Emergent Adverse Events at 21 days. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04850235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850235.